These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31268631)

  • 1. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry®.
    Ibrahim NE; Song Y; Cannon CP; Doros G; Russo P; Ponirakis A; Alexanian C; Januzzi JL
    ESC Heart Fail; 2019 Aug; 6(4):784-792. PubMed ID: 31268631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
    Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
    [No Abstract]   [Full Text] [Related]  

  • 3. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Sartipy U; Dahlström U; Fu M; Lund LH
    JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.
    Shiga T; Suzuki A; Haruta S; Mori F; Ota Y; Yagi M; Oka T; Tanaka H; Murasaki S; Yamauchi T; Katoh J; Hattori H; Kikuchi N; Watanabe E; Yamada Y; Haruki S; Kogure T; Suzuki T; Uetsuka Y; Hagiwara N;
    ESC Heart Fail; 2019 Jun; 6(3):475-486. PubMed ID: 30829002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction.
    Son MK; Park JJ; Lim NK; Kim WH; Choi DJ
    Heart; 2020 Aug; 106(15):1160-1168. PubMed ID: 32341140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.
    Farmakis D; Simitsis P; Bistola V; Triposkiadis F; Ikonomidis I; Katsanos S; Bakosis G; Hatziagelaki E; Lekakis J; Mebazaa A; Parissis J
    Clin Res Cardiol; 2017 May; 106(5):359-368. PubMed ID: 27999929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).
    Rickenbacher P; Kaufmann BA; Maeder MT; Bernheim A; Goetschalckx K; Pfister O; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2017 Dec; 19(12):1586-1596. PubMed ID: 28295985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
    Koh AS; Tay WT; Teng THK; Vedin O; Benson L; Dahlstrom U; Savarese G; Lam CSP; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1624-1634. PubMed ID: 28948683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China.
    Lyu S; Yu L; Tan H; Liu S; Liu X; Guo X; Zhu J
    BMC Cardiovasc Disord; 2019 Sep; 19(1):209. PubMed ID: 31477021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
    Chioncel O; Lainscak M; Seferovic PM; Anker SD; Crespo-Leiro MG; Harjola VP; Parissis J; Laroche C; Piepoli MF; Fonseca C; Mebazaa A; Lund L; Ambrosio GA; Coats AJ; Ferrari R; Ruschitzka F; Maggioni AP; Filippatos G
    Eur J Heart Fail; 2017 Dec; 19(12):1574-1585. PubMed ID: 28386917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.
    Tsuji K; Sakata Y; Nochioka K; Miura M; Yamauchi T; Onose T; Abe R; Oikawa T; Kasahara S; Sato M; Shiroto T; Takahashi J; Miyata S; Shimokawa H;
    Eur J Heart Fail; 2017 Oct; 19(10):1258-1269. PubMed ID: 28370829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction.
    Chen X; Savarese G; Dahlström U; Lund LH; Fu M
    Clin Res Cardiol; 2019 Dec; 108(12):1394-1405. PubMed ID: 30980205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain).
    Farré N; Lupon J; Roig E; Gonzalez-Costello J; Vila J; Perez S; de Antonio M; Solé-González E; Sánchez-Enrique C; Moliner P; Ruiz S; Enjuanes C; Mirabet S; Bayés-Genís A; Comin-Colet J;
    BMJ Open; 2017 Dec; 7(12):e018719. PubMed ID: 29273666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure.
    Savarese G; Vedin O; D'Amario D; Uijl A; Dahlström U; Rosano G; Lam CSP; Lund LH
    JACC Heart Fail; 2019 Apr; 7(4):306-317. PubMed ID: 30852236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.
    Abdul-Rahim AH; Shen L; Rush CJ; Jhund PS; Lees KR; McMurray JJV;
    Eur J Heart Fail; 2018 Jul; 20(7):1139-1145. PubMed ID: 29493058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of New-Onset Atrial Fibrillation in Heart Failure with Preserved, Mid-Range, and Reduced Ejection Fraction Following Acute Myocardial Infarction: Data from the NOAFCAMI-SH Registry.
    Hao C; Luo J; Liu B; Xu W; Li Z; Gong M; Qin X; Shi B; Wei Y
    Clin Interv Aging; 2022; 17():479-493. PubMed ID: 35444413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction.
    Teng TK; Tay WT; Dahlstrom U; Benson L; Lam CSP; Lund LH
    Int J Cardiol; 2018 Mar; 254():203-209. PubMed ID: 29407092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
    Lund LH; Claggett B; Liu J; Lam CS; Jhund PS; Rosano GM; Swedberg K; Yusuf S; Granger CB; Pfeffer MA; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2018 Aug; 20(8):1230-1239. PubMed ID: 29431256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications.
    Stolfo D; Uijl A; Vedin O; Strömberg A; Faxén UL; Rosano GMC; Sinagra G; Dahlström U; Savarese G
    JACC Heart Fail; 2019 Jun; 7(6):505-515. PubMed ID: 31146874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.
    Löfman I; Szummer K; Dahlström U; Jernberg T; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1606-1614. PubMed ID: 28371075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.